16-fluoroestradiol has been researched along with Fibroid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiyono, Y; Kurokawa, T; Mori, T; Okazawa, H; Yoshida, Y; Zhao, Z | 1 |
| Kiyono, Y; Kotsuji, F; Kurokawa, T; Okazawa, H; Tsujikawa, T; Yoshida, Y | 1 |
2 trial(s) available for 16-fluoroestradiol and Fibroid
| Article | Year |
|---|---|
18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Estradiol; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Immunohistochemistry; Ki-67 Antigen; Leiomyoma; Middle Aged; Positron-Emission Tomography; Sarcoma; Uterine Neoplasms | 2013 |
Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Topics: Adult; Aged; Biological Transport; Diagnosis, Differential; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Leiomyoma; Middle Aged; Positron-Emission Tomography; Prospective Studies; Sarcoma; Uterine Neoplasms | 2011 |